Chew Min Hoe, Yeh Yu-Ting, Toh Ee-Lin, Sumarli Stephen Aditya, Chew Ghee Kheng, Lee Lui Shiong, Tan Mann Hong, Hennedige Tiffany Priyanthi, Ng Shin Yi, Lee Say Kiat, Chong Tze Tec, Abdullah Hairil Rizal, Goh Terence Lin Hon, Rasheed Mohamed Zulfikar, Tan Kok Chai, Tang Choong Leong
Min Hoe Chew, Yu-Ting Yeh, Ee-Lin Toh, Stephen Aditya Sumarli, Choong Leong Tang, Department of Colorectal Surgery, Singapore General Hospital, Singapore 169608, Singapore.
World J Gastrointest Oncol. 2017 May 15;9(5):218-227. doi: 10.4251/wjgo.v9.i5.218.
To critically appraise short-term outcomes in patients treated in a new Pelvic Exenteration (PE) Unit.
This retrospective observational study was conducted by analysing prospectively collected data for the first 25 patients (16 males, 9 females) who underwent PE for advanced pelvic tumours in our PE Unit between January 2012 and October 2016. Data evaluated included age, co-morbidities, American Society of Anesthesiologists (ASA) score, Eastern Cooperative Oncology Group (ECOG) status, preoperative adjuvant treatment, intra-operative blood loss, procedural duration, perioperative adverse event, lengths of intensive care unit (ICU) stay and hospital stay, and oncological outcome. Quantitative data were summarized as percentage or median and range, and statistically assessed by the χ test or Fisher's exact test, as applicable.
All 25 patients received comprehensive preoperative assessment our dedicated multidisciplinary team approach. Long-course neoadjuvant chemoradiotherapy was provided, if indicated. The median age of the patients was 61.9-year-old. The median ASA and ECOG scores were 2 and 0, respectively. The indications for PE were locally invasive rectal adenocarcinoma ( = 13), advanced colonic adenocarcinoma ( = 5), recurrent cervical carcinoma ( = 3) and malignant sacral chordoma ( = 3). The procedures comprised 10 total PEs, 4 anterior PEs, 7 posterior PEs and 4 isolated lateral PEs. The median follow-up period was 17.6 mo. The median operative time was 11.5 h. The median volume of blood loss was 3306 mL, and the median volume of red cell transfusion was 1475 mL. The median lengths of ICU stay and of hospital stay were 1 d and 21 d, respectively. There was no case of mortality related to surgery. There were a total of 20 surgical morbidities, which occurred in 12 patients. The majority of the complications were grade 2 Clavien-Dindo. Only 2 patients experienced grade 3 Clavien-Dindo complications, and both required procedural interventions. One patient experienced grade 4a Clavien-Dindo complication, requiring temporary renal dialysis without long-term disability. The R0 resection rate was 64%. There were 7 post-exenteration recurrences during the follow-up period. No statistically significant relationship was found among histological origin of tumour, microscopic resection margin status and postoperative recurrence ( = 0.67). Four patients died from sequelae of recurrent disease during follow-up.
By utilizing modern assessment and surgical techniques, our PE Unit can manage complex pelvic cancers with acceptable morbidities, zero-rate mortality and equivalent oncologic outcomes.
对在一个新的盆腔廓清术(PE)治疗单元接受治疗的患者的短期结局进行严格评估。
本回顾性观察性研究通过分析前瞻性收集的2012年1月至2016年10月期间在我们的PE治疗单元因晚期盆腔肿瘤接受PE治疗的前25例患者(16例男性,9例女性)的数据进行。评估的数据包括年龄、合并症、美国麻醉医师协会(ASA)评分、东部肿瘤协作组(ECOG)状态、术前辅助治疗、术中失血、手术时间、围手术期不良事件、重症监护病房(ICU)住院时间和住院时间,以及肿瘤学结局。定量数据以百分比或中位数及范围进行总结,并根据适用情况通过χ检验或Fisher精确检验进行统计学评估。
所有25例患者均接受了我们专门的多学科团队方法进行的全面术前评估。如有指征,则给予长疗程新辅助放化疗。患者的中位年龄为61.9岁。ASA和ECOG评分的中位数分别为2和0。PE的指征为局部浸润性直肠腺癌(n = 13)、晚期结肠腺癌(n = 5)、复发性宫颈癌(n = 3)和恶性骶骨脊索瘤(n = 3)。手术包括10例全盆腔廓清术、4例前盆腔廓清术、7例后盆腔廓清术和4例孤立侧盆腔廓清术。中位随访期为17.6个月。中位手术时间为11.5小时。中位失血量为3306 mL,中位红细胞输注量为1475 mL。ICU住院时间和住院时间的中位数分别为1天和21天。没有与手术相关的死亡病例。共有20例手术并发症,发生在12例患者中。大多数并发症为2级Clavien-Dindo。只有2例患者发生3级Clavien-Dindo并发症,且均需要手术干预。1例患者发生4a级Clavien-Dindo并发症,需要临时肾脏透析但无长期残疾。R0切除率为64%。随访期间有7例盆腔廓清术后复发。在肿瘤组织学起源、显微镜下切缘状态和术后复发之间未发现统计学上的显著关系(P = 0.67)。4例患者在随访期间死于复发性疾病的后遗症。
通过采用现代评估和手术技术,我们的PE治疗单元能够以可接受的并发症发生率、零死亡率和相当的肿瘤学结局来处理复杂的盆腔癌症。